, anti-PD1 in less severe forms of melanoma in the future could also unveil a long-term impact of AKI episodes, Conflict of interest: None, vol.18, p.6
, , 2019.
The use of immunotherapy in the treatment of melanoma, J Hematol Oncol, vol.10, 2017. ,
Immunotherapy of melanoma, Contemp Oncol (Pozn), vol.22, issue.1A, pp.61-68, 2018. ,
Pembrolizumab: first global approval, Drugs, vol.74, issue.16, pp.1973-81, 2014. ,
Nivolumab in Previously Untreated Melanoma without BRAF Mutation, New England Journal of Medicine, vol.372, issue.4, pp.320-350, 2015. ,
Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials, JAMA Oncol, vol.1, issue.4, pp.433-473, 2015. ,
Anti-programmed-deathreceptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. The Lancet, vol.384, pp.1109-1126, 2014. ,
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. The Lancet Oncology, vol.16, pp.908-926, 2015. ,
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma, New England Journal of Medicine, vol.377, issue.19, pp.1824-1859, 2009. ,
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma, New England Journal of Medicine, vol.378, pp.1789-801, 2018. ,
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy, Eur J Cancer, vol.60, pp.190-209, 2016. ,
Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis. Front Pharmacol, vol.8, 2017. ,
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review, AJN, vol.45, issue.2, pp.160-169, 2017. ,
NToxicité rénale des immunothérapies : résultats préliminaires de l'étude ImmuNoTox. Néphrologie & Thérapeutique, vol.14, p.248, 2018. ,
Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review. The Oncologist, 2019. ,
Anticancer Drug-Induced Acute Kidney Injury. Kidney Int Rep, vol.2, pp.504-518, 2017. ,
Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient, Eur J Cancer, vol.67, pp.66-72, 2016. ,
Immune checkpoint therapy in proteinuric kidney disease, European Journal of Cancer, vol.95, pp.120-122, 2018. ,
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors, Kidney Int, vol.90, issue.3, pp.638-685, 2016. ,
Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients, American Journal of Kidney Diseases, vol.68, issue.2, pp.287-91, 2016. ,
Renal effects of immune checkpoint inhibitors, Nephrology Dialysis Transplantation, p.382, 2016. ,
Nivolumab-associated acute glomerulonephritis: a case report and literature review, BMC Nephrol, vol.17, 2016. ,
A case of IgA nephropathy after Nivolumab Therapy ,
Nivolumab-associated Nephrotic Syndrome in a Patient With Renal Cell Carcinoma: A Case Report, J Immunother, vol.40, issue.9, pp.345-353, 2017. ,
Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: singlecenter experience, J Immunother Cancer, vol.7, 2019. ,
Renal toxicities associated with pembrolizumab, Clin Kidney J, vol.12, issue.1, pp.81-89, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-02155026
Severe Hyponatremia and Immune Nephritis Following an Initial Infusion of Nivolumab, Target Oncol, vol.11, issue.4, pp.553-559, 2016. ,
Renal Complications of Immune Checkpoint Blockade, Curr Probl Cancer, vol.41, issue.2, pp.100-110, 2017. ,
, , 2018.
Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma, Oncologist, vol.22, issue.8, pp.963-71, 2017. ,
The association of BMI and outcomes in metastatic melanoma: A retrospective, multicohort analysis of patients treated with targeted therapy, immunotherapy, or chemotherapy, Lancet Oncol, vol.19, issue.3, pp.310-332, 2018. ,
Obesity induced T cell dysfunction and implications for cancer immunotherapy, Curr Opin Immunol, vol.51, pp.181-187, 2018. ,
Obesity as an immune-modifying factor in cancer immunotherapy, J Leukoc Biol, vol.104, issue.3, pp.487-97, 2018. ,
Gut Microbiome and Obesity: A Plausible Explanation for Obesity. Curr Obes Rep, vol.4, pp.250-61, 2015. ,
Alteration of intestinal permeability: the missing link between gut microbiota modifications and inflammation in obesity? ,
URL : https://hal.archives-ouvertes.fr/hal-01331313
, Med Sci (Paris), vol.32, issue.5, pp.461-470, 2016.
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients, Science, vol.359, issue.6371, pp.104-112, 201805. ,
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients, Science, vol.359, issue.6371, pp.97-103, 2018. ,
LBA2Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients, Ann Oncol [Internet], vol.29, issue.suppl_10, 2018. ,
Do proton pump inhibitors modulate the efficacy of anti-PD-1/PD-L1 therapy? A retrospective study, Journal of Oncology Pharmacy Practice, vol.25, issue.3, pp.762-766, 2019. ,
Proton pump inhibitors and response to immune checkpoint inhibitors: Single center study. JCO, vol.37, pp.14092-14092, 2019. ,
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer, JCO, vol.36, issue.28, pp.2872-2880, 2018. ,
Early Use of Systemic Corticosteroids in Patients with Advanced NSCLC Treated with Nivolumab -Journal of Thoracic Oncology, 2019. ,
The impact of immune checkpoint inhibitor-related adverse events and their immunosuppressive treatment on patients' outcomes, Journal of Immunotherapy and Precision Oncology, vol.1, issue.1, p.7, 2018. ,
Association Between Immune-Related Adverse Events and Clinical Efficacy in Patients with Melanoma Treated With Nivolumab: A Multicenter Retrospective Study, Clinical Therapeutics, vol.41, issue.1, pp.59-67, 2019. ,
,
, Baseline characteristics of the two groups: AKI versus control (NA: not available, missing data)
, Kaplan Meier Survival curve in patients treated for a metastatic melanoma with anti-PD1 antibodies (Nivolumab or Pembrolizumab)
, Overall survival; 2B. Survival considering the occurrence of AKI, p.2
, Kaplan Meier overall survival curve in patients treated for a metastatic melanoma with anti-PD1 antibodies (Nivolumab or Pembrolizumab), univariate Cox regression analysis: 3A. Anti-PD1: line number of treatments. 3B. BMI. 3C. Corticosteroids as a baseline treatment
, Kaplan Meier survival curve considering the occurrence of AKI in patients treated for a metastatic melanoma with anti-PD1 antibodies (Nivolumab or Pembrolizumab), p.univariate
, Cox regression analysis: 4A. ACE inhibitors or AIIRA. 4B. Chronic kidney disease 4C. Corticosteroids as a baseline treatment 4D
, Kaplan Meier survival curve considering a composite primary outcome (AKI or death) in patients treated for a metastatic melanoma with anti-PD1 antibodies (Nivolumab or Pembrolizumab)
Corticosteroids as a baseline treatment 5D. PPI as a baseline treatment ,
, 5%) Dyslipidemia 55/233 (23.6%) NA : 6/239 (2,5%) Autoimmune Disease, .9%) Corticosteroid daily dose (mg) -Mean (range) of anti-PD1 (mg) : -Mean (range), pp.80-16980
, BMI (kg/m2): -Mean (range)
, Hypertension
, Corticosteroid, vol.12, issue.41
, Corticosteroid daily dose (mg): -Mean (range)
, Melanoma staging (AJCC) : -IIIB -IIIC -IV
,
, N cycles of anti-PD1: -Mean (range)
, Cumulated doses of anti-PD1 (mg): -Mean (range) -Median